Physician profile
Thuy Nguyen
NPI 1720459662
$4,417.69
in general payments reported to CMS, 2019-2025
33 companies · $20.25 in 2025
The $20.25 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,741 · 2022: $2,013 · 2023: $613 · 2024: $30.87 · 2025: $20.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,017.81 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $981.81 | 2021-2023 | |
| Amgen INC. | $411.32 | 2021-2022 | |
| Amarin Pharma, INC. | $283.82 | 2021-2022 | |
| Lilly USA, LLC | $263.55 | 2021-2023 | Mounjaro, Reyvow, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $145.14 | 2021-2023 | |
| Astellas Pharma US INC | $135.54 | 2021-2023 | Myrbetriq, Veozah |
| Esperion Therapeutics, INC. | $133.86 | 2021 | |
| Glaxosmithkline, LLC. | $129.46 | 2023 | Bexsero, Shingrix, Rotarix |
| Astrazeneca Pharmaceuticals Lp | $127.51 | 2021-2025 | Farxiga |
| Pfizer INC. | $113.03 | 2021-2023 | |
| Organon LLC | $91.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $91.30 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $60.09 | 2021 | |
| Merck Sharp & Dohme LLC | $43.69 | 2021-2023 | Belsomra, Steglatro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $41.01 | 2022 | |
| Neos Therapeutics, Lp | $35.78 | 2021 | |
| Horizon Therapeutics Plc | $35.53 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.87 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.08 | 2021-2022 | |
| Sanofi Pasteur INC. | $29.73 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.17 | 2022 | |
| Eisai INC. | $19.51 | 2021 | |
| Emd Serono, INC. | $17.99 | 2023 | Serostim |
| Corium, LLC | $16.16 | 2023 | Adlarity |
| Ironwood Pharmaceuticals, INC | $15.89 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.09 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.22 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.01 | 2021 | |
| Abbott Laboratories | $12.89 | 2022 | |
| Upsher-Smith Laboratories LLC | $12.09 | 2022 | |
| Currax Pharmaceuticals LLC | $12.02 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.